COMMUNIQUÉS West-GlobeNewswire

Haleon Canada Appoints Daniela Cavinatto as General Manager
04/08/2026
MISSISSAUGA, Ontario, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Haleon, a leading global consumer company, today announced the appointment of Daniela Cavinatto as General Manager, Canada. Daniela joins Haleon with more than 25 [...]
Haleon Canada nomme Daniela Cavinatto au poste de directrice générale
04/08/2026
MISSISSAUGA, Ontario, 04 août 2026 (GLOBE NEWSWIRE) -- Haleon, un chef de file mondial dans le domaine des biens de consommation, a annoncé aujourd’hui la nomination de Daniela Cavinatto au poste de directrice générale [...]
ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities
04/08/2026
TYLER, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company, today announced it has completed the transition of its [...]
Northwestern Memorial Hospital Earns U.S. News Honor Roll Recognition for 15th Consecutive Year
04/08/2026
Multiple Northwestern Medicine hospitals achieved national specialty rankings, top regional placements and high-performing distinctions across key areas of care CHICAGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- For the 15 th [...]
Amae Health Partners with Google Health Enterprise to Bring Wearable Data Integration to the Treatment of Complex Mental Health Conditions
04/08/2026
This collaboration reinforces Amae Health's precision psychiatry model, bringing the same level of measurement and precision to severe mental illness that is traditionally applied to physical healthcare SAN FRANCISCO, [...]
H1 Partners with Novo Nordisk to Scale AI-Driven Clinical Development
04/08/2026
Partnership builds on Novo Nordisk’s AI and digital foundation to enhance clinical trial design and execution through AI-enabled workflows and insights NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- H1 today announced a [...]
RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties
04/08/2026
Glen Rock, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases [...]
Capra Biosciences Advances Domestic Manufacturing of Essential Medicines with Continued HHS Support
04/08/2026
Follow-on investment builds on prior work to advance seven pharmaceutical ingredients toward commercial-scale domestic production STERLING, Va., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Capra Biosciences, Inc., a [...]
Integrity Urgent Care Clinic Opens in Murphy, Texas
04/08/2026
Murphy’s newest urgent care clinic offers accessible, high-quality health care you can count on Key facts of this press release: Integrity Urgent Care opened a clinic in Murphy, Texas, on Aug. 3, 2026 New Murphy clinic [...]
Integrity Urgent Care Clinic Opens in Conroe, Texas
04/08/2026
Conroe’s newest urgent care clinic offers accessible, high-quality health care you can count on Key facts of this press release: Integrity Urgent Care opened a clinic in Conroe, Texas, on Aug. 3, 2026 New Conroe clinic [...]
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
04/08/2026
Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform Access [...]
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
04/08/2026
HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company’s investigational FAK inhibitor narmafotinib in combination with Lilly’s [...]
Cannabix Targets Combat Sports Market for Commercial Rollout of Marijuana Breath Test at ABC Boxing & MMA Conference
04/08/2026
VANCOUVER, British Columbia, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”), a developer of marijuana and alcohol breath testing [...]
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
04/08/2026
Conference Call and Webcast Scheduled for August 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage [...]
Wave Life Sciences to Present at Upcoming Investor Conferences
04/08/2026
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
04/08/2026
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Sofwave Medical Reports Second Quarter and First Half 2026 Financial Results and Business Highlights
04/08/2026
Second quarter revenue of $30M, +43% year-over-year growth; IFRS gross margin of 76.5% Second quarter usage fee revenue of $13.9M, 52.2% year-over-year growth First half revenue of $54.4M, +44% year-over-year growth; [...]
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
04/08/2026
-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of other pending [...]
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
04/08/2026
TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase 2 clinical trial of [...]

Pages